Recent Articles

Autism: The challenges and opportunities of an adult diagnosis

Hospice care: Overview of a compassionate approach to end-of-life care

Foot pain: A look at why your feet might hurt

Matcha: A look at possible health benefits

Wildfires: How to cope when smoke affects air quality and health

Forearm workouts: Strengthening grip for everyday function

Depression symptoms: Recognizing common and lesser-known symptoms

Medication side effects: What are your options?

Independent living with home care assistance: Balancing autonomy and support

Dialysis: What to expect from this life-changing — and lifesaving — treatment

Adam S. Cheifetz, MD

Contributor

Dr. Adam Cheifetz is director of the center for inflammatory bowel disease and medical director of infusion services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School. He is a well-recognized leader in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases. He is involved in multiple research projects relating to IBD, and has published over 200 articles and chapters on the subject.

His research currently focuses on therapeutic drug monitoring and optimizing the use of biologics through the proactive use of drug concentrations and antibodies, and he has published extensively in this area. Dr. Cheifetz was the first to demonstrate that proactive monitoring of infliximab and adalimumab concentrations and dosing to a therapeutic window improves outcomes when compared to standard of care.